Pozzi, C.; Dipartimento di Biotecnologie, Chimica e Farmacia, Università di Siena, Siena, Italy
De Luca, F.; Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italy
Benvenuti, M.; Dipartimento di Biotecnologie, Chimica e Farmacia, Università di Siena, Siena, Italy
Poirel, L.; INSERM European Unit (LEA), University of Fribourg, Fribourg, Switzerland, Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg, Switzerland
Nordmann, P.; INSERM European Unit (LEA), University of Fribourg, Fribourg, Switzerland, Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science, University of Fribourg, Fribourg, Switzerland
Rossolini, G. M.; Dipartimento di Biotecnologie Mediche, Università di Siena, Siena, Italy, SOD Microbiologia e Virologia, Azienda Ospedaliera Universitaria Careggi, Florence, Italy, Dipartimento di Medicina Sperimentale e Clinica, Università di Firenze, Florence, Italy
Mangani, S.; Dipartimento di Biotecnologie, Chimica e Farmacia, Università di Siena, Siena, Italy, Magnetic Resonance Center CERM, Università di Firenze, Sesto Fiorentino, Italy
Docquier, Jean-Denis ; Université de Liège - ULiège > Département des sciences de la vie > Centre d'ingénierie des protéines
Language :
English
Title :
Crystal structure of the Pseudomonas aeruginosa BEL-1 extended-spectrum β-lactamase and its complexes with moxalactam and imipenem
Bush K, Jacoby GA 2010. Updated functional classification of β-lactamases. Antimicrob Agents Chemother 54:969-976. http://dx.doi.org/10.1128/AAC.01009-09.
Poirel L, Brinas L, Verlinde A., Ide L, Nordmann P. 2005. BEL-1, a novel clavulanic acid-inhibited extended-spectrum β-lactamase, and the class 1 integron In120 in Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:3743-3748. http://dx.doi.org/10.1128/AAC.49.9.3743-3748.2005.
Poirel L, Docquier JD, De Luca F, Verlinde A, Ide L., Rossolini GM, Nordmann P. 2010. BEL-2, an extended-spectrum β-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa. Antimicrob Agents Chemother 54:533-535. http://dx.doi.org/10.1128/AAC.00859-09.
Benvenuti M, Mangani S. 2007. Crystallization of soluble proteins in vapor diffusion for X-ray crystallography. Nat Protoc 2:1633-1651. http://dx.doi.org/10.1038/nprot.2007.198.
Battye TG, Kontogiannis L, Johnson O., Powell HR, Leslie AG. 2011. iMOSFLM: a new graphical interface for diffraction-image processing with MOSFLM. Acta Crystallogr D Biol Crystallogr 67:271-281. http://dx.doi.org/10.1107/S0907444910048675.
Evans P. 2006. Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr 62:72-82. http://dx.doi.org/10.1107/S0907444905036693.
Winn MD, Ballard CC, Cowtan K.D., Dodson EJ, Emsley P, Evans PR, Keegan R.M., Krissinel EB, Leslie AG, McCoy A, McNicholas S.J., Murshudov GN, Pannu NS, Potterton EA, Powell H.R., Read RJ, Vagin A, Wilson KS. 2011. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67:235-242. http://dx.doi.org/10.1107/S0907444910045749.
Ibuka AS, Ishii Y, Galleni M., Ishiguro M, Yamaguchi K, Frere J.M., Matsuzawa H., Sakai H. 2003. Crystal structure of extended-spectrum β-lactamase Toho-1: insights into the molecular mechanism for catalytic reaction and substrate specificity expansion. Biochemistry 42:10634-10643. http://dx.doi.org/10.1021/bi0342822.
Vagin A, Teplyakov A. 1997. MOLREP: an automated program for molecular replacement. J Appl Crystallogr 30:1022-1025. http://dx.doi.org/10.1107/S0021889897006766.
Murshudov GN, Skubák P, Lebedev A.A., Pannu NS, Steiner RA, Nicholls RA, Winn M.D., Long F., Vagin AA. 2011. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr 67:355-367. http://dx.doi.org/10.1107/S0907444911001314.
Emsley P, Lohkamp B, Scott W.G., Cowtan K. 2010. Features and development of Coot. Acta Crystallogr D Biol Crystallogr 66:486-501. http://dx.doi.org/10.1107/S0907444910007493.
Langer G, Cohen SX, Lamzin V.S., Perrakis A. 2008. Automated macromolecular model building for X-ray crystallography using ARP/wARP version 7. Nat Protoc 3:1171-1179. http://dx.doi.org/10.1038/nprot.2008.91.
Laskowski RA, MacArthur MW, Moss D.S., Thornton JM. 1993. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr 26:283-291. http://dx.doi.org/10.1107/S0021889892009944.
McNicholas S, Potterton E, Wilson K.S., Noble MEM. 2011. Presenting your structures: the CCP4mg molecular-graphics software. Acta Crystallogr Sect D 67:386-394. http://dx.doi.org/10.1107/S0907444911007281.
Ruggiero M, Kerff F, Herman R., Sapunaric F, Galleni M, Gutkind G., Charlier P, Sauvage E, Power P. 2014. Crystal structure of the extended-spectrum β-lactamase PER-2 and insights into the role of specific residues in the interaction with β-lactams and β-lactamase inhibitors. Antimicrob Agents Chemother 58:5994-6002. http://dx.doi.org/10.1128/AAC.00089-14.
Matagne A, Lamotte-Brasseur J, Frere JM. 1998. Catalytic properties of class A β-lactamases: efficiency and diversity. Biochem J 330:581-598. http://dx.doi.org/10.1042/bj3300581.
Banerjee S, Pieper U, Kapadia G., Pannell LK, Herzberg O. 1998. Role of the w-loop in the activity, substrate specificity, and structure of class A β-lactamase. Biochemistry 37:3286-3296. http://dx.doi.org/10.1021/bi972127f
Maveyraud L, Mourey L, Kotra L.P., Pedelacq JD, Guillet V, Mobashery S, Samama JP 1998. Structural basis for clinical longevity of carbapenem antibiotics in the face of challenge by the common class A β-lactamases from the antibiotic-resistant bacteria. J Am Chem Soc 120:9748-9752. http://dx.doi.org/10.1021/ja9818001.
Docquier JD, Benvenuti M, Calderone V., Rossolini GM, Mangani S. 2011. Structure of the extended-spectrum β-lactamase TEM-72 inhibited by citrate. Acta Crystallogr F Struct Biol Cryst Commun 67:303-306. http://dx.doi.org/10.1107/S1744309110054680.
Petrella S, Ziental-Gelus N, Mayer C., Renard M, Jarlier V, Sougakoff W. 2008. Genetic and structural insights into the dissemination potential of the extremely broad-spectrum class A β-lactamase KPC-2 identified in an Escherichia coli strain and an Enterobacter cloacae strain isolated from the same patient in France. Antimicrob Agents Chemother 52:3725-3736. http://dx.doi.org/10.1128/AAC.00163-08.
Docquier JD, Benvenuti M, Calderone V., Giuliani F, Kapetis D, De Luca F, Rossolini GM, Mangani S. 2010. Crystal structure of the narrow-spectrum OXA-46 class D β-lactamase: relationship between active-site lysine carbamylation and inhibition by polycarboxylates. Antimicrob Agents Chemother 54:2167-2174. http://dx.doi.org/10.1128/AAC.01517-09.
Beck J, Vercheval L, Bebrone C., Herteg-Fernea A, Lassaux P, Marchand-Brynaert J. 2009. Discovery of novel lipophilic inhibitors of OXA-10 enzyme (class D β-lactamase) by screening amino analogs and homologs of citrate and isocitrate. Bioorg Med Chem Lett 19:3593-3597. http://dx.doi.org/10.1016/j.bmcl.2009.04.149.
Matagne A, Lamotte-Brasseur J, Dive G., Knox JR, Frere JM. 1993. Interactions between active-site-serine β-lactamases and compounds bearing a methoxy side chain on the alpha-face of the β-lactam ring: kinetic and molecular modelling studies. Biochem J 293:607-611. http://dx.doi.org/10.1042/bj2930607.
Nishikawa J, Watanabe F, Shudou M., Terui Y, Narisada M. 1987. Proton NMR study of degradation mechanisms of oxacephem derivatives with various 3'-substituents in alkaline solution. J Med Chem 30:523-527. http://dx.doi.org/10.1021/jm00386a014.
Patera A, Blaszczak LC, Shoichet BK 2000. Crystal structures of substrate and inhibitor complexes with AmpC β-lactamase: possible implications for substrate-assisted catalysis. J Am Chem Soc 122:10504-10512. http://dx.doi.org/10.1021/ja001676x.
Trehan I, Beadle BM, Shoichet BK 2001. Inhibition of AmpC β-lactamase through a destabilizing interaction in the active site. Biochemistry 40:7992-7999. http://dx.doi.org/10.1021/bi010641m.
Ehmann DE, Jahic H, Ross P.L., Gu RF, Hu J, Kern G, Walkup G.K., Fisher SL. 2012. Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad Sci USA 109:11663-11668. http://dx.doi.org/10.1073/pnas.1205073109.
Lahiri SD, Mangani S, Durand-Reville T, Benvenuti M., De Luca F, Sanyal G, Docquier JD 2013. Structural insight into potent broad-spectrum inhibition with reversible recyclization mechanism: avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-lactamases. Antimicrob Agents Chemother 57:2496-2505. http://dx.doi.org/10.1128/AAC.02247-12.
Ehmann DE, Jahic H, Ross P.L., Gu RF, Hu J, Durand-Reville TF, Lahiri S, Thresher J., Livchak S, Gao N, Palmer T., Walkup GK, Fisher SL. 2013. Kinetics of avibactam inhibition against class A, C, and D β-lactamases. J Biol Chem 288:27960-27971. http://dx.doi.org/10.1074/jbc.M113.485979.
Sougakoff W, L'Hermite G, Pernot L, Naas T., Guillet V, Nordmann P, Jarlier V., Delettre J. 2002. Structure of the imipenem-hydrolyzing class A β-lactamase SME-1 from Serratia marcescens. Acta Crystallogr D Biol Crystallogr 58:267-274. http://dx.doi.org/10.1107/S0907444901019606.
Frase H, Smith CA, Toth M, Champion M.M., Mobashery S., Vakulenko SB. 2011. Identification of products of inhibition of GES-2 β-lactamase by tazobactam by x-ray crystallography and spectrometry. J Biol Chem 286: 14396-14409. http://dx.doi.org/10.1074/jbc.M110.208744.
Ke W, Bethel CR, Thomson J.M., Bonomo RA, van den Akker F. 2007. Crystal structure of KPC-2: insights into carbapenemase activity in class A β-lactamases. Biochemistry 46:5732-5740. http://dx.doi.org/10.1021/bi700300u.
Swaren P, Maveyraud L, Raquet X., Cabantous S, Duez C, Pedelacq J.D., Mariotte-Boyer S, Mourey L, Labia R., Nicolas-Chanoine MH, Nordmann P, Frere J.M., Samama JP. 1998. X-ray analysis of the NMC-A β-lactamase at 1.64-A resolution, a class A carbapenemase with broad substrate specificity. J Biol Chem 273:26714-26721. http://dx.doi.org/10.1074/jbc.273.41.26714.
Lamotte-Brasseur J., Dive G, Dideberg O., Charlier P, Frere JM, Ghuysen JM 1991. Mechanism of acyl transfer by the class A serine β-lactamase of Streptomyces albus G. Biochem J 279:213-221. http://dx.doi.org/10.1042/bj2790213.
Tranier S, Bouthors AT, Maveyraud L, Guillet V., Sougakoff W, Samama JP. 2000. The high resolution crystal structure for class A β-lactamase PER-1 reveals the bases for its increase in breadth of activity. J Biol Chem 275:28075-28082. http://dx.doi.org/10.1074/jbc.M003802200.
Wang X, Minasov G, Shoichet BK 2002. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J Mol Biol 320:85-95. http://dx.doi.org/10.1016/S0022-2836(02)00400-X.
Raquet X, Vanhove M, Lamotte-Brasseur J, Goussard S., Courvalin P, Frère JM. 1995. Stability of TEM β-lactamase mutants hydrolyzing third generation cephalosporins. Proteins Gen 23:63-72. http://dx.doi.org/10.1002/prot.340230108.
Huang W, Palzkill T. 1997. A natural polymorphism in β-lactamase is a global suppressor. Proc Natl Acad Sci USA 94:8801-8806. http://dx.doi.org/10.1073/pnas.94.16.8801.
Frère J.M., Sauvage E, Kerff F. 2016. From "an enzyme able to destroy penicillin" to carbapenemases: 70 years of β-lactamase misbehaviour. Curr Drug Targets 17:974-982. http://dx.doi.org/10.2174/1389450116666151001112859.
Docquier JD, Lamottte-Brasseur J, Galleni M., Amicosante G, Frère JM, Rossolini GM. 2003. On functional and structural heterogeneity of VIM-type metallo-β-lactamases. J Antimicrob Chemother 51:257-266.
De Meester F., Joris B, Reckinger G., Bellefroid-Bourguignon C, Frère JM, Waley SG. 1987. Automated analysis of enzyme inactivation phenomena. Application to β-lactamases and DD-peptidases. Biochem Pharmacol 36:2393-2403.
Borgianni L, Vandenameele J, Matagne A., Bini L, Bonomo RA, Frère JM, Rossolini G.M., Docquier JD. 2010. Mutational analysis of VIM-2 reveals an essential determinant for metallo-β-lactamase stability and folding. Antimicrob Agents Chemother 54:3197-3204. http://dx.doi.org/10.1128/AAC.01336-09.